Energy News / Shareholders Foundation, Inc.

NASDAQ:MNLO Former Employee Alert: Investigation over Potential Wrongdoing at Menlo Therapeutics Inc

Via: ReleaseWire

Updated 11:45 AM CDT, Tue, August 28,2018

An investigation on behalf of former employees of Menlo Therapeutics Inc. (NASDAQ: MNLO) concerning potential breaches of fiduciary duties was announced and former employees of Menlo Therapeutics Inc. should contact the Shareholders Foundation.

San Diego, CA -- (SBWIRE) -- 08/28/2018 -- An investigation on behalf of former employees of Menlo Therapeutics Inc. (NASDAQ: MNLO) concerning potential Breaches of Fiduciary Duty was announced.

Former employees of Menlo Therapeutics Inc. (NASDAQ: MNLO), have certain options and should contact the Shareholders Foundation, Inc. at mail(at)shareholdersfoundation.com or call +1(858) 779 - 1554.

According to the investigation by a law firm under ERISA employees of Menlo Therapeutics Inc. (NASDAQ: MNLO), may be eligible to file a complaint for putting stock options at risk if they can prove their employer violated its fiduciary duty to them.

On March 28, 2018, Menlo Therapeutics Inc. reported its fourth quarter and full year 2017 financial results and provided its financial outlook for the full year 2018. Menlo Therapeutics Inc. reported that its annual Total Revenue rose from $0.674 million in 2016 to $4.582 million in 2017 and that its Net loss rose from $14.068 million to $29.076 million in 2017.

Furthermore, Menlo Therapeutics Inc. stated that for the full year 2018, it expects operating expenses in the range of approximately$77.0 to $87.0 million, including stock-based compensation of approximately $3.0 to $6.0 million.

Shares of Menlo Therapeutics Inc. (NASDAQ: MNLO) reached $38.824 per share on March 28, 2018.

On May 9, 2018, Menlo Therapeutics Inc reported its first quarter 2018 financial results. Menlo Therapeutics Inc reported a net loss of $12.7 million for the first quarter of 2018, compared to a net loss of $5.5 million for the same period in 2017. Furthermore, Menlo Therapeutics Inc, adjusted its financial outlook for the full year 2018. Menlo Therapeutics Inc said that it is lowering its operating expense guidance for the full year 2018 to a range of approximately $68.0 to $78.0 million.

Those who purchased shares of Menlo Therapeutics Inc. (NASDAQ: MNLO) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com

The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, , which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigation, and/or settlements are not filed/reached and/or related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

For more information on this press release visit:
http://www.sbwire.com/press-releases/nasdaqmnlo-former-employee-alert-investigation-over-potential-wrongdoing-at-menlo-therapeutics-inc-1036785.htm

Media Relations Contact
Michael Daniels
858-779-1554
Email: Click to Email Michael Daniels
Web: http://www.ShareholdersFoundation.com